Thermo Fisher Scientific Inc. will invest $150 million at three Pharma Services business sites in Monza and Ferentino, Italy, and Greenville, NC to add capacity for sterile liquid and lyophilized product development and commercial manufacturing.
Each site will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months, the company reported in a March 18, 2019 press statement announcing the investment.
"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. "We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them."
Source: Thermo Fisher Scientific
